Secondary Central Nervous System Lymphoma Registry

Secondary Central Nervous System Lymphoma Registry - Charité

Rekrutierend

NCT-Nummer:
NCT05114330

Studienbeginn:
Juni 2011

Letztes Update:
27.11.2023

Wirkstoff:
-

Indikation (Clinical Trials):
Lymphoma

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
Charite University, Berlin, Germany

Collaborator:
-

Kontakt

Stefan Habringer, MD
Kontakt:
E-Mail: stefan.habringer@charite.de» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Charité - Universitätsmedizin, Med. Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie (CBF)
12200 Berlin
(Berlin)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Ulrich Keller, MD, Prof.
Phone: +4930 450513447
E-Mail: ulrich.keller@charite.de

Stefan Habringer, MD
Phone: +4930450613549
E-Mail: stefan.habringer@charite.de» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

The observational study is to be conducted in inpatient clinics, outpatient clinics and by

oncology physicians in private practice. The investigators will be invited to participate by

the Charité - CNS Lymphoma Working Group (Charité AG ZNSL) or the Competence Network

Malignant Lymphomas (KML). When a patient is reported, the personal data of the physician

including the patient will be recorded and compiled in the form of a list documentation.

All patients with SCNSL can and should be included in the study regardless of which therapy

options are used and regardless of whether it is a first-line treatment, the treatment of a

recurrence or a maintenance therapy for SCNSL. No intervention is associated with the conduct

of the observational study with regard to the selection and implementation of the specific

therapeutic regimen, diagnostics, and examination frequency during and after treatment.

The following information should be documented:

- Patient demographics and medical history

- Tumor extent at the time of initial diagnosis and CNS involvement

- Prior therapy

- General condition

- Therapy regimen for the CNS involvement

- Response

- Adverse drug reactions

- Tolerability of therapy: acute toxicity

- Chronic therapy toxicity, especially late neurotoxicity

- Time to treatment failure (relapse or progression)

- Death from any cause

Ein-/Ausschlusskriterien

Inclusion Criteria:

• All patients with SCNSL can and should be included in the registry regardless of which

treatment options are used and whether the treatment being given is first-line, recurrence,

or maintenance therapy for SCNSL.

Exclusion Criteria:

• None

Studien-Rationale

Primary outcome:

1. Description of different therapeutic regimens (Time Frame - Through study completion, an average of 3 years):
Description of different therapeutic regimens

2. Outcome of different therapeutic regimens (Time Frame - Through study completion, an average of 3 years):
Overall Survival

3. Outcome of different therapeutic regimens (Time Frame - Through study completion, an average of 3 years):
Progression Free Survival

Studien-Arme

Cohort 1
Systemic (= localized outside the CNS) lymphoma with secondary CNS involvement at initial diagnosis
Cohort 2
CNS relapse of previously systemic lymphoma

Quelle: ClinicalTrials.gov